GUB014295
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
AbbVie · Phase 1 · Completed · Enrollment 76
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.